The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Follow-up results of NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with trastuzumab (CT+H) followed by adjuvant H versus CT alone, in patients with HER2-positive locally advanced breast cancer.
Luca Gianni
Consultant or Advisory Role - AstraZeneca (U); Boehringer Ingelheim (U); Celgene (U); GlaxoSmithKline (U); Novartis (U); Pfizer (U); Roche/Genentech
Wolfgang Eiermann
Consultant or Advisory Role - Roche
Honoraria - Roche
Vladimir Semiglazov
No relevant relationships to disclose
Alexey Manikhas
No relevant relationships to disclose
Ana Lluch
No relevant relationships to disclose
Sergei Tjulandin
No relevant relationships to disclose
Milvia Zambetti
No relevant relationships to disclose
Federico Vazquez
No relevant relationships to disclose
Mikhail J. Byakhov
No relevant relationships to disclose
Mikhail Lichinitser
No relevant relationships to disclose
Miguel Angel Climent
Honoraria - Roche
Eva Ciruelos
No relevant relationships to disclose
Belen Ojeda
No relevant relationships to disclose
Mauro Mansutti
No relevant relationships to disclose
Alla Bozhok
No relevant relationships to disclose
Domenico Magazzu
No relevant relationships to disclose
Jutta Steinseifer
Employment or Leadership Position - Roche
Pinuccia Valagussa
No relevant relationships to disclose
Jose Baselga
Consultant or Advisory Role - Roche